MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024


	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Balance at January 1, 2024		3,650,278	$	2.82		5.00
Issued		2,622,230		1.58
Exercised		—		—
Expired		—		—
Balance at March 31, 2024		6,272,508	$	2.30		2.76

Summary of Activity and Information regarding Outstanding and Exercisable Options

The following table summarizes the activity and information regarding MAIA’s outstanding and exercisable options for the three months ended March 31, 2024:


	Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Balance at January 1, 2024		7,750,152		$	2.53		7.29
Granted		984,455			1.42
Exercised		—			—
Cancelled/forfeited		(673,629	)		3.58
Balance at March 31, 2024		8,060,978		$	2.31		7.14		2,588,003
Options exercisable at March 31, 2024		6,649,017		$	2.29		6.84		2,237,777

Assumptions used in Calculating Value of Options Granted

The value of option grants is calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the three months ended March 31, 2024 and 2023:


	2024		2023
Risk-free interest rate	3.98% - 4.49%		3.64% - 4.23%
Expected term (in years)	5 - 6.08		5 - 6.08
Expected volatility	95% - 152.5%		99.6% - 101.1%
Expected dividend yield		-		—

Summary of Stock Based Compensation Expense

Stock based compensation related to the Company’s stock plans are as follows:


	Three Months Ended
	March 31,
	2024		2023
General and administrative	$	230,989	$	256,677
Research and development		118,976		280,845
Total stock-based compensation	$	349,965	$	537,522